NGM Biopharmaceuticals, Inc. (NGM): Price and Financial Metrics
NGM Price/Volume Stats
| Current price | $1.54 | 52-week high | $4.69 |
| Prev. close | $1.56 | 52-week low | $0.60 |
| Day low | $1.54 | Volume | 2,390,800 |
| Day high | $1.57 | Avg. volume | 1,467,160 |
| 50-day MA | $1.54 | Dividend yield | N/A |
| 200-day MA | $1.54 | Market Cap | 128.53M |
NGM Stock Price Chart Interactive Chart >
NGM Biopharmaceuticals, Inc. (NGM) Company Bio
NGM Biopharmaceuticals, Inc. engages in the discovery and development of therapeutics for major diseases with an initial focus on cardio-metabolic and liver diseases. Its portfolio if composed of product candidates which focuses on non-alcoholic steatohepatitis, type 2 diabetes, obesity, oncology and age-related macular degeneration. The company was founded by Jin-Long Chen in 2008 and is headquartered in South San Francisco, CA.
Latest NGM News From Around the Web
Below are the latest news stories about NGM BIOPHARMACEUTICALS INC that investors may wish to consider to help them evaluate NGM as an investment opportunity.
Here's Why We're A Bit Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, although... |
NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®--As previously reported, the ALPINE 4 study met its primary endpoint, with aldafermin 3 mg demonstrating a statistically significant reduction in Enhanced Liver Fibrosis (ELF) score compared to placebo after 48 weeks of treatment-- --ELF, an FDA-approved non-invasive blood test, can be used to predict liver-related events in patients with nonalcoholic steatohepatitis (NASH) and compensated cirrhosis-- --Dose-dependent improvements reported across histologic and multiple non-invasive secondary e |
NGM Bio to Participate in Upcoming Investor ConferencesSOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming 6th Annual Evercore ISI HealthCONx Conference and will present an overview of the company and provide a business update. Management will also be available |
NGM Biopharmaceuticals Inc (NGM) Reports Q3 2023 Financial ResultsCompany's net loss decreases year-over-year, cash runway extends into mid-2025 |
NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Misses Revenue EstimatesNGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 12.50% and 67.67%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock? |
NGM Price Returns
| 1-mo | -0.65% |
| 3-mo | 14.07% |
| 6-mo | 87.92% |
| 1-year | -61.50% |
| 3-year | -94.31% |
| 5-year | -90.11% |
| YTD | 79.28% |
| 2023 | -82.89% |
| 2022 | -71.65% |
| 2021 | -41.54% |
| 2020 | 63.85% |
| 2019 | N/A |
Loading social stream, please wait...